World's Best Scientists 2026 revealed!
Dongsheng Tu

Dongsheng Tu

D-Index & Metrics

Medicine

D-Index
86
Citations
51769
World Ranking
13847
National Ranking
570

Overview

Dongsheng Tu is affiliated with Queen's University in Canada and has a body of research primarily focused on medicine, with a significant emphasis on oncology. Their work spans a range of subfields including oncology, statistics and probability, cancer research, pulmonary and respiratory medicine, and economics and econometrics.

The scientist's research topics cover detailed studies and treatments in colorectal cancer, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and statistical methods in clinical trials. Other notable areas include genetic factors in colorectal cancer and ovarian cancer diagnosis and treatment.

Frequent co-authors of Dongsheng Tu include Derek J. Jonker, Jonathan M. Loree, Christopher J. O'Callaghan, Hagen F. Kennecke, and Chris J. O'Callaghan.

Important publication venues for their research include the Journal of Clinical Oncology, Statistics in Medicine, Clinical Cancer Research, European Journal of Cancer, and Pain.

Significant recent papers by Dongsheng Tu are:

  • Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer, 2020, JAMA Oncology
  • Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology
  • Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer, 2024, New England Journal of Medicine
  • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies, 2022, Nature Communications
  • The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma, 2022, Nature Communications

Best Publications

  • Erlotinib in previously treated non-small-cell lung cancer.

    Frances A. Shepherd;José Rodrigues Pereira;Tudor Ciuleanu;Eng Huat Tan

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

    Christos S Karapetis;Shirin Khambata-Ford;Derek J Jonker;Chris J O'Callaghan

  • The jackknife and bootstrap

    Jun Shao;Dongsheng Tu

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

    Christine M. Ribic;Daniel J. Sargent;Malcolm J. Moore;Malcolm J. Moore;Stephen N. Thibodeau

  • Cetuximab for the Treatment of Colorectal Cancer

    Derek J Jonker;Chris J O'Callaghan;Christos S Karapetis;John R Zalcberg

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Morphine, Gabapentin, or Their Combination for Neuropathic Pain

    Ian Gilron;Joan M. Bailey;Dongsheng Tu;Ronald R. Holden

  • Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    Paul E. Goss;James N. Ingle;José E. Alés-Martínez;Angela M. Cheung

  • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

    M. N. Levine;V. H. Bramwell;K. I. Pritchard;B. D. Norris

  • Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

    Wendy De Roock;Derek J Jonker;Federica Di Nicolantonio;Andrea Sartore-Bianchi

  • Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

    Astec;P Blake;Ann Marie Swart

  • HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

    Kathleen I. Pritchard;Lois E. Shepherd;Frances P. O'Malley;Irene L. Andrulis

  • Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma

    Aileen M. Davis;Aileen M. Davis;Brian O'Sullivan;Robert Turcotte;Robert Bell;Robert Bell

  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Paul E. Goss;James N. Ingle;Kathleen I. Pritchard;Nicholas J. Robert

  • Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

    Emmanuel Mitry;Anthony L.A. Fields;Harry Bleiberg;Roberto Labianca

  • Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

    R. Pearcey;M. Brundage;P. Drouin;J. Jeffrey

  • Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial

    Ian Gilron;Ian Gilron;Joan M Bailey;Joan M Bailey;Dongsheng Tu;Ronald R Holden

  • Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;J. Hamm;J. Dancey;P. D. Eisenberg

  • Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark

Frequent Co-Authors

Lesley Seymour
Lesley Seymour Queen's University
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Paul E. Goss
Paul E. Goss Harvard University
John R. Zalcberg
John R. Zalcberg Monash University
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
James N. Ingle
James N. Ingle Mayo Clinic
John Simes
John Simes University of Sydney
Elizabeth A. Eisenhauer
Elizabeth A. Eisenhauer Queen's University
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready to commit to a full medical degree, there are flexible online pathways to consider. The demand for nurses continues to grow, and online nursing programs provide multiple entry points for students with diverse backgrounds.

For those seeking advanced qualifications, online nursing doctoral programs can help you reach leadership or teaching roles without relocating. If you're a registered nurse looking to enhance your credentials, exploring the rn to bsn online cost can help you find affordable options and accelerate your career.

Non-nurses interested in fast-tracking their education can research direct entry msn programs for non nurses online for efficient routes into advanced nursing roles. For those concerned about admissions, there are also easy nursing programs to get into that provide accessible opportunities.

Exploring these related online degrees and career pathways offers flexibility, affordability, and the chance to enter rewarding healthcare careers—often from the comfort of your home.

Best Scientists Citing Dongsheng Tu

Trending Scientists

Recently Published Articles